Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth quadruple therapy versus clarithromycin quadruple therapy for Helicobacter pylori eradication
PACTR202304550587833Phase 4Recruiting
- Sponsor
- GalPharma
- Start
- Mar 2023
- Countries
- 1
01
Overview
Phase 4 trial in Helicobacter pylori infection (2 arms), sponsored by GalPharma. Primary endpoint: Helicobacter pylori eradication rate. Started Mar 2023; status: recruiting.
02
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on PACTR202304550587833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202304550587833.